WAVE Life Sciences (NASDAQ:WVE) shares gap up following earnings beat. October 27, 2026 Key points. * WAVE Life Sciences shares opened higher after the company reported quarterly earnings of $0.30 per share versus analysts' expected loss of $0.33, while revenue of $13.16 million exceeded the $4.51 million consensus estimate. * Wall Street's outlook is generally positive, with a consensus "Moderate Buy" rating and a $21.53 price target, although analyst views range from "Strong Buy" to "Sell." * Institutional investors hold 89.73% of the stock and several major funds increased their positions, while company insiders sold 23,564 shares worth $132,476 over the past three months. * Is WAVE Life Sciences on your watchlist? MarketBeat All Access adds unlimited watchlist stocks and real-time alerts for $149 a year, a rate that never goes up while you are a member. WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) gapped up before the market opened on Tuesday following a better than expected earnings announcement. The stock had previously closed at $3.21, but opened at $3.55. WAVE Life Sciences shares last traded at $3.3450, with a volume of 331,315 shares changing hands. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.03. The business had revenue of $13.16 million for the quarter, compared to analyst estimates of $4.51 million. WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%. Wall Street analysts forecast growth. Several equities research analysts have issued reports on the stock. LADENBURG THALM/SH SH initiated coverage on shares of WAVE Life Sciences in a research report on Thursday, October 1st. They set a "buy" rating and a $10.00 target price for the company. Mizuho decreased their price objective on shares of WAVE Life Sciences from $27.00 to $23.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 4th. Zacks Research cut shares of WAVE Life Sciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 19th. Weiss Ratings restated a "sell (d-)" rating on shares of WAVE Life Sciences in a research report on Thursday, October 15th. Finally, Wedbush set a $13.00 price target on WAVE Life Sciences in a research report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, WAVE Life Sciences has a consensus rating of "Moderate Buy" and a consensus price target of $21.53. Insiders place their bets. In other news, Director Heidi L. Wagner sold 7,000 shares of WAVE Life Sciences stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total transaction of $42,070.00. Following the transaction, the director directly owned 44,930 shares of the company's stock, valued at $270,029.30. The trade was a 13.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Adrian Rawcliffe sold 12,700 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total transaction of $67,183.00. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 23,564 shares of company stock valued at $132,476. Insiders own 24.34% of the company's stock. Institutional inflows and outflows. Large investors have recently added to or reduced their stakes in the business. Readystate Asset Management LP purchased a new stake in WAVE Life Sciences in the 2nd quarter worth $27,465,000. Squarepoint Ops LLC boosted its position in shares of WAVE Life Sciences by 68.0% during the 2nd quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company's stock valued at $14,766,000 after acquiring an additional 1,029,052 shares during the last quarter. Pictet Asset Management Holding SA increased its position in WAVE Life Sciences by 42.6% in the first quarter. Pictet Asset Management Holding SA now owns 1,149,127 shares of the company's stock worth $8,202,000 after purchasing an additional 343,226 shares during the last quarter. Renaissance Technologies LLC increased its position in WAVE Life Sciences by 152.6% in the first quarter. Renaissance Technologies LLC now owns 597,220 shares of the company's stock worth $4,330,000 after purchasing an additional 360,800 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in WAVE Life Sciences by 12.4% during the first quarter. Bank of New York Mellon Corp now owns 361,204 shares of the company's stock valued at $2,619,000 after purchasing an additional 39,759 shares in the last quarter. 89.73% of the stock is owned by hedge funds and other institutional investors. WAVE Life Sciences price performance. The firm has a market cap of $655.78 million, a P/E ratio of -3.05 and a beta of -1.43. The company's 50-day simple moving average is $4.20 and its 200 day simple moving average is $7.71. WAVE Life Sciences company profile. WAVE Life Sciences Ltd. NASDAQ: WVE is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases. Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider WAVE Life Sciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list. While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets. Continue following MarketBeat

WAVE Life Sciences (WVE) expected to release quarterly earnings on Tuesday. WAVE Life Sciences (NASDAQ:WVE - Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect WAVE Life Sciences to announce earnings of ($0.34) per share and revenue of $4.51 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET. WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.04). The business had revenue of $2.27 million for the quarter, compared to analysts' expectations of $7.45 million. WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 50.36%. On average, analysts expect WAVE Life Sciences to post ($1.12) EPS for the current fiscal year and ($1.29) EPS for the next fiscal year. WAVE Life Sciences trading down 1.5%. Shares of WVE opened at $3.37 on Thursday. The stock has a 50 day moving average of $4.31 and a 200 day moving average of $5.64. The company has a market capitalization of $664.67 million, a price-to-earnings ratio of -3.09 and a beta of -1.43. WAVE Life Sciences has a 12 month low of $3.04 and a 12 month high of $21.73. Insider buying and selling. In related news, Director Heidi Wagner sold 7,000 shares of WAVE Life Sciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total value of $42,070.00. Following the sale, the director owned 44,930 shares of the company's stock, valued at approximately $270,029.30. The trade was a 13.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Adrian Rawcliffe sold 12,700 shares of the company's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total value of $67,183.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 23,564 shares of company stock worth $132,476 in the last ninety days. 24.34% of the stock is currently owned by insiders. Analyst ratings changes. Several research analysts have weighed in on WVE shares. HC Wainwright reissued a "buy" rating on shares of WAVE Life Sciences in a research report on Friday, October 2nd. JPMorgan Chase & Co. started coverage on WAVE Life Sciences in a research report on Wednesday, September 23rd. They set a "neutral" rating for the company. Mizuho lowered their target price on WAVE Life Sciences from $27.00 to $23.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 4th. LADENBURG THALM/SH SH initiated coverage on shares of WAVE Life Sciences in a report on Thursday, October 1st. They issued a "buy" rating and a $10.00 price target on the stock. Finally, Zacks Research lowered shares of WAVE Life Sciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, WAVE Life Sciences has an average rating of "Moderate Buy" and a consensus price target of $21.53. WAVE Life Sciences company profile. WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases. Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders. Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Wave Life Sciences to host virtual Research Day on Wednesday, November 4, 2026. CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) - Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced it will host a virtual Research Day on Wednesday, November 4, 2026 at 9:30 a.m. ET. During the event, Wave will share new data highlighting its differentiated RNA medicines platform, including its best-in-class chemistry, hepatic and extra-hepatic capabilities, and RNAi, RNA editing, and bifunctional modalities. The event will also feature perspectives on PNPLA3 I148M liver disease and the opportunity for an RNA editing correction approach from Arun J. Sanyal, MD, FAASLD, a leading hepatologist. Dr. Sanyal is a Z Reno Vlahcevic Professor of Medicine and Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University (VCU) School of Medicine. Research Day Webcast A webcast of the event can be accessed by visiting "Investor Events" on the investor relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the event can join the audio-conferencing link available here. Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website. About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's PRISM(R) platform combines multiple RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington's disease, as well as several preclinical programs utilizing the company's versatile RNA medicines platform. Driven by the calling to "Reimagine Possible," Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn. Media: Katie Sullivan Senior Director, Corporate Communications +1 617-949-2936 [email protected]